Who is the manufacturer of Mirikizumab?

Mirikizumab is a humanized IgG4 monoclonal antibody that targets moderately to severely active ulcerative colitis and works primarily by suppressing specific cytokines in the immune system. The drug is developed and produced by Eli Lilly and Company, a world-renowned pharmaceutical company.

Founded in 1876Eli Lilly is a prestigious pharmaceutical company dedicated to developing innovative treatments for unmet medical needs. As an industry pioneer, Lilly continues to promote the development and launch of new drugs in multiple therapeutic areas, especially in immunology and inflammatory diseases.

The development of Militizumab began based on in-depth research on the biological properties of interleukin-23 (IL-23). Researchers have found that IL-23 plays a key role in the mucosal inflammation process and affects the occurrence and development of a variety of chronic inflammatory diseases by regulating the functions of T cells and innate immune cells. Therefore, intervention targeting IL-23 is considered an important strategy to improve the symptoms of these diseases. Eli Lilly has invested a lot of resources in this field and actively developed related drugs in order to contribute to improving the quality of life of patients.

Milizumab has demonstrated good efficacy and safety in preclinical experiments and clinical trials at all stages. In clinical studies, militizumab effectively inhibits the interaction between IL-23 and its receptor by selectively binding to the p19 subunit of IL-23, thereby reducing the release of pro-inflammatory cytokines and chemokines. Many results show significant improvements in clinical remission and response rates in patients treated with militizumab. In addition, the safety of militizumab has been well evaluated, with side effects generally being mild and manageable.

Reference materials:https://en.wikipedia.org/wiki/Mirikizumab